⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71630 | 0.80 | — | — | |
| SCHEMBL1108358 | 0.80 | — | — | |
| SCHEMBL3804192 | 0.77 | TSHR (0.50) | — | |
| Hydrochloric Acid SCHEMBL29274502 | 0.77 | TSHR (0.50) | — | |
| SCHEMBL31178732 | 0.75 | CYP1A2 (0.54) | — | |
| SCHEMBL4412822 | 0.72 | — | — | |
| SCHEMBL30839807 | 0.72 | TSHR (0.46) | — | |
| SCHEMBL31366816 | 0.72 | — | — | |
| SCHEMBL16347053 | 0.72 | TSHR (0.46) | — | |
| SCHEMBL10664478 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4638434-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250241193-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-07-24 | — | — | US | disclosed |
| US-12302752-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-13 | — | — | US | disclosed |
| US-20250073341-A1 | BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-06 | — | — | US | disclosed |
| WO-2025010314-A1 | UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-09 | — | — | WO | disclosed |
| US-12161722-B2 | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-12-10 | — | — | US | disclosed |
| US-20240285778-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-29 | — | — | US | disclosed |
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2015095265-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-9006477-B2 | Method for producing nitrobenzene compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20140163256-A1 | METHOD FOR PRODUCING NITROBENZENE COMPOUND | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |